MedTrace Logo

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00119626 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1700

Last updated 2010-11-15

No results posted yet for this study

Summary

This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.

Conditions

  • Cerebral Stroke
  • Ischemic Attack, Transient

Interventions

DRUG

NXY-059

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca NXY-059 Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00119626 on ClinicalTrials.gov